79 research outputs found
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
BACKGROUND:Convalescent plasma is frequently administered to patients with Covid-19 and hasbeen reported, largely on the basis of observational data, to improve clinical outcomes.Minimal data are available from adequately powered randomized, controlled trials.
METHODS:We randomly assigned hospitalized adult patients with severe Covid-19 pneumoniain a 2:1 ratio to receive convalescent plasma or placebo. The primary outcome wasthe patient?s clinical status 30 days after the intervention, as measured on a six-pointordinal scale ranging from total recovery to death.
RESULTS:A total of 228 patients were assigned to receive convalescent plasma and 105 toreceive placebo. The median time from the onset of symptoms to enrollment inthe trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the mostfrequent severity criterion for enrollment. The infused convalescent plasma had amedian titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to1:3200]. No patients were lost to follow-up. At day 30 day, no significant differencewas noted between the convalescent plasma group and the placebo group in thedistribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83(95% confidence interval [CI], 0.52 to 1.35; P=0.46). Overall mortality was 10.96%in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of â0.46 percentage points (95% CI, â7.8 to 6.8). Total SARS-CoV-2 antibodytiters tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups.
CONCLUSIONS:no significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo.(PlasmAr ClinicalTrials.gov number, NCT04383535.)Fil: Simonovich, Ventura A.. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; ArgentinaFil: Burgos Pratx, Leandro D.. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; ArgentinaFil: Scibona, Paula. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; ArgentinaFil: Beruto, Maria Valeria. No especifĂca;Fil: Vallone, Miguel Gabriel. No especifĂca;Fil: VĂĄzquez, C.. No especifĂca;Fil: Savoy, N.. No especifĂca;Fil: Giunta, Diego Hernan. No especifĂca;Fil: PĂ©rez, L.G.. No especifĂca;Fil: SĂĄnchez, M.L.. No especifĂca;Fil: Gamarnik, Andrea Vanesa. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Instituto de Investigaciones BioquĂmicas de Buenos Aires. FundaciĂłn Instituto Leloir. Instituto de Investigaciones BioquĂmicas de Buenos Aires; ArgentinaFil: Ojeda, D.S.. No especifĂca;Fil: Santoro, D.M.. No especifĂca;Fil: Camino, P. J.. No especifĂca;Fil: Antelo, S.. No especifĂca;Fil: Rainero, K.. No especifĂca;Fil: Vidiella, G. P.. No especifĂca;Fil: Miyazaki, E. A.. No especifĂca;Fil: Cornistein, W.. No especifĂca;Fil: Trabadelo, O. A.. No especifĂca;Fil: Ross, F. M.. No especifĂca;Fil: Spotti, M.. No especifĂca;Fil: Funtowicz, G.. No especifĂca;Fil: Scordo, W. E.. No especifĂca;Fil: Losso, M. H.. No especifĂca;Fil: Ferniot, I.. No especifĂca;Fil: Pardo, P. E.. No especifĂca;Fil: Rodriguez, E.. No especifĂca;Fil: Rucci, P.. No especifĂca;Fil: Pasquali, J.. No especifĂca;Fil: Fuentes, N. A.. No especifĂca;Fil: Esperatti, M.. No especifĂca;Fil: Speroni, G. A.. No especifĂca;Fil: Nannini, Esteban. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Centro CientĂfico TecnolĂłgico Conicet - Rosario. Instituto de InmunologĂa Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias MĂ©dicas. Instituto de InmunologĂa Clinica y Experimental de Rosario; ArgentinaFil: Matteaccio, A.. No especifĂca;Fil: Michelangelo, H.G.. No especifĂca;Fil: Follmann, D.. No especifĂca;Fil: Lane, H. Clifford. No especifĂca;Fil: Belloso, Waldo Horacio. Hospital Italiano. Departamento de Medicina. Servicio de Clinica Medica.; Argentin
Numerical methods for the design and description of in vitro expansion processes of human mesenchymal stem cells
Human mesenchymal stem cells (hMSCs) are a valuable source of cells for clinical applications (e.g., treatment of acute myocardial infarction or inflammatory diseases), especially in the field of regenerative medicine. However, for autologous (patient-specific) and allogeneic (off-the-shelf) hMSC-based therapies, in vitro expansion is necessary prior to the clinical application in order to achieve the required cell numbers. Safe, reproducible, and economic in vitro expansion of hMSCs for autologous and allogeneic therapies can be problematic because the cell material is restricted and the cells are sensitive to environmental changes. It is beneficial to collect detailed information on the hydrodynamic conditions and cell growth behavior in a bioreactor system, in order to develop a so called âDigital Twinâ of the cultivation system and expansion process. Numerical methods, such as Computational Fluid Dynamics (CFD) which has become widely used in the biotech industry for studying local characteristics within bioreactors or kinetic growth modelling, provide possible solutions for such tasks.
In this review, we will present the current state-of-the-art for the in vitro expansion of hMSCs. Different numerical tools, including numerical fluid flow simulations and cell growth modelling approaches for hMSCs, will be presented. In addition, a case study demonstrating the applicability of CFD and kinetic growth modelling for the development of an microcarrier-based hMSC process will be shown
Recommended from our members
CONSIDERATIONS ON THE DISTRIBUTION OF IONS BETWEEN AN ORGANIC SOLUTION OF ALKYL-AMMONIUM SALTS AND AN AQUEOUS SOLUTION OF INORGANIC SALTS IN THE PRESENCE OF HOMOPOLYMERS AND HETEROPOLYMERS IN THE ORGANIC PHASE
Considerations on the Distribution of Ions between an Organic Solution of Alkylammonium Salts and an Aqueous Solution of Inorganic Salts in the Presence of Homopolymers and Heteropolymers in the Organic Phase
Flavone derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
Flavone carbamoylated and sulfated derivatives, in form of salts with pharmaceutically acceptable metals or organic bases, have interesting antielastase activit
- âŠ